Human IgE antibodies specific for cow's milk proteins (Milk-specific IgE)

Human IgE antibodies specific for cow's milk proteins are the primary mediators of IgE-mediated cow's milk allergy (CMA), which is one of the most prevalent food allergies in early childhood [NIH, 2024]. These antibodies are produced by B cells in response to sensitization to specific milk allergens, most notably caseins (Bos d 8) and whey proteins like alpha-lactalbumin (Bos d 4) and beta-lactoglobulin (Bos d 5) [Labcorp, 2024]. In an allergic individual, these IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils [Patsnap, 2025]. Upon subsequent ingestion of cow's milk, the allergens cross-link the surface-bound IgE, triggering the rapid release of inflammatory mediators such as histamine, leukotrienes, and cytokines [IgGenix, 2024]. This process leads to clinical symptoms ranging from mild urticaria and gastrointestinal distress to severe, life-threatening anaphylaxis [MDPI, 2024]. Therapeutic strategies targeting these antibodies include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE in the circulation and prevent its binding to cellular receptors, thereby increasing the threshold for allergic reactions and improving the safety of oral immunotherapy [NIH, 2024]. Additionally, monitoring the levels of these specific IgE antibodies serves as a critical diagnostic and prognostic tool in managing milk allergy [Labcorp, 2024].

Other names

Cow's milk-specific IgEMilk-specific IgEsIgE to cow's milk proteinsAnti-milk IgEBos d-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, which downregulates receptor expression and inhibits the release of inflammatory mediators.